510(k) Report

510(k) · Cleared

Cleared

Dexcom G6 Continuous Glucose Monitoring (CGM) System

K201328510(k) TraditionalCleared Jul 15, 2021422-day reviewClass II21 CFR 862.1355

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Dexcom, Inc. · QBJ Integrated Continuous Glucose Monitoring System, Factory Calibrated

Cleared on Jul 15, 2021 as substantially equivalent to K200876 (Dexcom, Inc., 2020) after a 422-day review. Its family tree reaches back 4 generations to 2018. 2 of the 22 devices in its family, counting itself, have a Class I recall. 15 later devices descend from it.

Decided
Jul 15, 2021
Review
422 days
Class
Class II
Product code
QBJ
Recalls
None
Predicates
1

Its longest line of descent runs back 4 generations to DEN170088 (2018). 6 ancestors in all. 15 later devices descend from it, 2 citing it directly. 2 of the 22 devices in this family, counting this one, have a Class I recall.

Other ancestors, by year clearedDescendants, by year cleared 2019: 1 other ancestor2018: 1 other ancestor2022: 2 descendants cleared, 1 with a Class I recall12023: 2 descendants cleared, 1 with a Class I recall12024: 3 descendants cleared2025: 3 descendants cleared2026: 5 descendants clearedDEN170088 · Dexcom G6 Continuous Glucose Monitoring System · Dexcom, Inc. · 2018K182041 · Dexcom G6 Glucose Program Continuous Glucose Monitoring System · Dexcom, Inc. · 2018K191450 · Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program Continuous Glucose Monitoring System and Dexcom Pro Q Continuous Glucose Monitoring System · Dexcom, Inc. · 2019 · recalledK200876 · Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program Continuous Glucose Monitoring System · Dexcom, Inc. · 2020 · recalled201620182020202220242026
Other ancestors, by generationDescendants, by generation 3 generations back: 2 other ancestors 1 generation forward: 2 descendants, 1 with a Class I recall12 generations forward: 2 descendants, 1 with a Class I recall13 generations forward: 2 descendants4 generations forward: 4 descendants5 generations forward: 4 descendants6 generations forward: 1 descendant K200876 · Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program Continuous Glucose Monitoring System · Dexcom, Inc. · 2020 · recalledK191450 · Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program Continuous Glucose Monitoring System and Dexcom Pro Q Continuous Glucose Monitoring System · Dexcom, Inc. · 2019 · recalledK182041 · Dexcom G6 Glucose Program Continuous Glucose Monitoring System · Dexcom, Inc. · 2018DEN170088 · Dexcom G6 Continuous Glucose Monitoring System · Dexcom, Inc. · 20180+5
  1. Root · 4 generations backDEN170088 Dexcom G6 Continuous Glucose Monitoring SystemDexcom, Inc. · 2018
  2. 3 generations backK182041 Dexcom G6 Glucose Program Continuous Glucose Monitoring SystemDexcom, Inc. · 2018
  3. 2 generations backK191450 Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose…Dexcom, Inc. · 2019 · Recalled
  4. 1 generation backK200876 Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose…Dexcom, Inc. · 2020 · Recalled
  5. This deviceK201328 Dexcom G6 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc. · 2021
  6. Descendant · cites it directly · 12 of its ownK213919 Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2022 · Recalled (Class I)
  7. Descendant · 2 generations on · 11 of its ownK231081 Dexcom G7 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc. · 2023 · Recalled
  8. Descendant · 3 generations on · 5 of its ownK234133 Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2024
  9. Descendant · 4 generations on · 4 of its ownK240902 Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2024 · Recalled
  10. Descendant · 3 generations on · 4 of its ownK234070 Stelo Glucose Biosensor SystemDexcom, Inc. · 2024

Showing 5 of 15 descendants. See all descendants

Descendants cleared per year

2022: 22023: 22024: 32025: 32026: 5
2022high 5 (2026) · low 2 (2022)2026

Class I recalls in this family

Most influential descendants

Showing 5 of 15 · See all
  • K213919Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2022 · cites it directly12descendants
  • K231081Dexcom G7 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc. · 2023 · 2 generations on11descendants
  • K234133Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2024 · 3 generations on5descendants
  • K240902Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2024 · 4 generations on4descendants
  • K234070Stelo Glucose Biosensor SystemDexcom, Inc. · 2024 · 3 generations on4descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−4DEN170088Dexcom G6 Continuous Glucose Monitoring SystemDexcom, Inc.2018—
−3K182041Dexcom G6 Glucose Program Continuous Glucose Monitoring SystemDexcom, Inc.2018—
−2K191450Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program…Dexcom, Inc.20192
−1K200876Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program…Dexcom, Inc.20201
0 (this device)K201328Dexcom G6 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc.2021—
+1K213919Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc.2022Class I
+2K231081Dexcom G7 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc.20231
+3K234133Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc.2024—
+4K240902Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc.20243
+3K234070Stelo Glucose Biosensor SystemDexcom, Inc.2024—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
201810
201910

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202221
202321
202430
202530
202650
FIG. 1 — Lineage of K201328, 2018–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

2 devices in this family have a Class I recall. A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QBJ device

  1. #1 K253737 Dexcom G7 Continuous Glucose Monitoring (CGM)…score 16.5 · 10 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K200876Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program Continuous…
Cleared while this submission was under review
Summary page 5
…on Product Code QBJ Review Panel Clinical Chemistry 5.3 PREDICATE DEVICE: Dexcom G6 Continuous Glucose Monitoring (CGM) System (K200876) 5.4 DEVICE DESCRIPTION: The Dexcom G6 Continuous Glucose Monitoring System (G6 System) is an interoperable connected d…
Dexcom, Inc.20201

Also cleared against K200876: 1 other device →

What descends from it? (15)

See all 15

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K213919Dexcom G7 Continuous Glucose Monitoring System Class IDexcom, Inc.202212
K221259Dexcom G6 Continuous Glucose Monitoring (CGM) System, Dexcom G6 Glucose Program…Dexcom, Inc.20221

Has anything in its family been recalled? (2 Class I)

No FDA recall names this device.

Relatives with a Class I recall

Class I is FDA’s most serious recall class. A recall in the family tree is context for this device, not evidence about it.

  • K213919Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2022 · Cites it directly · ◆ in the 2022 descendants bar of FIG. 14 Class I recalls
  • K223931Dexcom G6 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc. · 2023 · 2 generations on · ◆ in the 2023 descendants bar of FIG. 12 Class I recalls

What does this lineage say?

  • The line of descent spans 3 years and passes through 1 company; a new generation was cleared every 8 months on median.
  • 2 of the 6 ancestors have a recall of any class.
  • Of its descendants, K213919 (Dexcom, Inc., 2022) has gone furthest, with 12 descendants of its own.
  • 1 other device also cites its predicate K200876.

How does its category compare?

All QBJ devices

QBJ Integrated Continuous Glucose Monitoring System, Factory Calibrated: FDA decisions, review times, recalls and adverse event reports over 20 years. 2021, this device’s year, is highlighted.

FDA decisions per year · QBJ

2in 2025

2018: 12019: 22020: 12021: 12022: 22023: 42024: 32025: 22026 (partial year): 2
2007high 4 (2023) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QBJ

59in 2024

2023: 89 days median2024: 59 days median
2007high 89 (2023) · low 59 (2024)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QBJ

4so far in 2026, the most since 2007

2025: 2, 1 Class I2026 (partial year): 4
2007high 4 (2026) · low 0 (2007)2026

Class I (1 since 2007) Class II/III not classified

Adverse event reports per year · QBJ

374,651in 2025

2007: 32018: 37,1062019: 80,7742020: 200,7382021: 254,8332022: 232,2882023: 273,5652024: 347,1242025: 374,651
2007high 374,651 (2025) · low 0 (2008)2025

MAUDE reports naming product code QBJ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—03
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20181—037,106
20192—080,774
20201—0200,738
20211—0254,833
20222—0232,288
20234890273,565
20243590347,124
20252—2 (1)374,651
20262—4—

What is it indicated for?

The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons age 2 years and older. The Dexcom G6 System is intended to replace fmgerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 System results should be based on the glucose trends and several sequential readings over time. The Dexcom G6 System…

Read the full statement (132 words)

The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons age 2 years and older.

The Dexcom G6 System is intended to replace fmgerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 System results should be based on the glucose trends and several sequential readings over time. The Dexcom G6 System also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments.

The Dexcom G6 System is also intended to autonomously communicate with digitally connected devices, including automated insulin dosing (AID) systems. The Dexcom G6 System can be used alone or in conjunction with these digitally connected medical devices for the purpose of managing diabetes.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K201328: Dexcom G6 Continuous Glucose Monitoring (CGM) System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K201328

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026